

1 **Title**

2 **Pairwise and Higher-Order Epistatic Interactions Have a Significant Impact on**
3 **Bronchodilator Drug Response in African American Youth with Asthma**

4 **Authors**

5 Magaña J¹, Contreras MG^{1,2}, Keys KL^{1,3}, Risse-Adams O^{1,4,5}, Goddard PC^{1,6}, Zeiger AM^{1,7}, Mak ACY¹,
6 Elhawary JR¹, Samedy-Bates LA⁸, Lee E¹, Thakur N¹, Hu D¹, Eng C¹, Salazar S¹, Huntsman S¹, Hu T⁹,
7 Burchard EG^{1,8}, and White MJ¹.

8 1. Department of Medicine, University of California, San Francisco, CA

9 2. Department of Biology, San Francisco State University, CA

10 3. Berkeley Institute for Data Science, University of California, Berkeley, CA

11 4. Lowell Science Research Program, Lowell High School, San Francisco, CA

12 5. Department of Biology, University of California, Santa Cruz, CA

13 6. Department of Genetics, Stanford University, Stanford, CA

14 7. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

15 8. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA

16 9. School of Computing, Queen's University, Kingston, ON, Canada

17

18 **Corresponding Author:**

19 Marquitta J. White

20 University of California San Francisco

21 1550 4th Street, UCSF Rock Hall, Box 2911

22 San Francisco, CA 94158

23 marquitta.white@ucsf.edu

24 **Abstract**

25 *Background:* Asthma is one of the leading chronic illnesses among children in the United States. Asthma
26 prevalence is higher among African Americans (11.2%) compared to European Americans (7.7%).
27 Bronchodilator medications are part of the first-line therapy, and the rescue medication, for acute
28 asthma symptoms. Bronchodilator drug response (BDR) varies substantially among different
29 racial/ethnic groups. Asthma prevalence in African Americans is only 3.5% higher than that of European
30 Americans, however, asthma mortality among African Americans is four times that of European
31 Americans; variation in BDR may play an important role in explaining this health disparity. To improve
32 our understanding of disparate health outcomes in complex phenotypes such as BDR, it is important to
33 consider interactions between environmental and biological variables.

34 *Results:* We evaluated the impact of pairwise and three-variable interactions between environmental,
35 social, and biological variables on BDR in 617 African American youth with asthma using Visualization of
36 Statistical Epistasis Networks (ViSEN). ViSEN is a non-parametric entropy-based approach able to
37 identify interaction effects. We performed analyses in the full dataset and in sex-stratified subsets.
38 Analysis in the full dataset identified six significant interactions associated with BDR, the strongest of
39 which was an interaction between prenatal smoke exposure, age, and global African ancestry (IG: 1.09%,
40 $p=0.005$). Sex-stratified analyses yielded additional significant, but divergent, results for females and
41 males, indicating the presence of sex-specific effects.

42 *Conclusions:* Our study identified novel interaction effects significantly influencing BDR in African
43 American children with asthma. Notably, we found that the impact of higher-order interactions was
44 greater than that of pairwise or main effects on BDR highlighting the complexity of the network of
45 genetic and environmental factors impacting this phenotype. Several associations uncovered by ViSEN
46 would not have been detected using regression-based methods emphasizing the importance of

47 employing statistical methods optimized to detect both linear and non-linear interaction effects when
48 studying complex phenotypes such as BDR. The information gained in this study increases our
49 understanding and appreciation of the complex nature of the interactions between environmental and
50 health-related factors that influence BDR and will be invaluable to biomedical researchers designing
51 future studies.

52 **Keywords**

53 Gene-environment interactions non-parametric methods asthma drug response health disparities
54 pediatric asthma

55 **Abbreviations**

56 BDR – Bronchodilator drug response; MI – Mutual Information; IG – Information Gain; ViSEN –
57 Visualization of Statistical Epistasis Networks

58 **Background**

59 Asthma is an inflammatory disease of the lower respiratory tract, characterized by symptomatic
60 difficulty of breathing in affected individuals.¹ In the United States (U.S.), asthma is one of the leading
61 chronic illnesses among children.² Asthma is also the most disparate common disease in pediatric
62 populations, with asthma prevalence, morbidity, and mortality rates varying widely by racial/ethnic
63 group.³ Specifically, rates of asthma prevalence and mortality are two and four times higher,
64 respectively, in African American children compared to European American children.³ Measures of
65 asthma morbidity, including emergency department visits and missed school days, are also higher in
66 African American children compared to their European American counterparts.⁴ Despite the higher
67 asthma burden in the African American community, this population has been historically
68 underrepresented in asthma research.^{5,6} Recent years have shown an increase in the inclusion of
69 African Americans in large scale biomedical studies; however, this population is still comparatively
70 understudied when contrasted with efforts aimed at European American populations.^{5,6}

71 The disparity in asthma health outcomes across racial/ethnic groups may be due in part to a
72 difference in drug response. Bronchodilators, specifically short acting β_2 -agonist medications such as
73 albuterol, are the most commonly prescribed asthma medication in the United States.^{7,8}
74 Bronchodilator drug response (BDR) is the amount of airway obstruction that is reversible after the
75 administration of bronchodilator medication. BDR varies significantly between racial/ethnic groups.⁹⁻
76 ¹¹ Alarminglly, compared to other racial/ethnic groups, African American children with moderate-to-
77 severe asthma respond poorly to bronchodilators, ranking second worst among all demographic
78 groups.¹¹

79 The estimated genetic heritability of bronchodilator drug response is approximately 28.5%.¹² However,
80 this estimate only represents the additive effect of each genetic factor on BDR variability and does not
81 account for gene-environment, gene-gene, or variant-variant effects.

82 For example, while measures of air pollution, socioeconomic status, genetic ancestry, and obesity
83 have all been independently associated with BDR and/or other asthma-related phenotypes, the
84 amount of variation in BDR independently explained by each of these variables is relatively small,
85 leaving a large portion of the variation in BDR undefined.^{7,13-16} A portion of the undefined variation in
86 BDR is likely explained by gene-gene or gene-environment interactions.¹⁷ While these interactions
87 could be linear or non-linear in nature, historically research in complex phenotypes, such as BDR, has
88 traditionally focused primarily on the identification of linear interaction effects through the use of
89 regression-based methods. Synergistic non-linear interactions (epistatic interactions) have recently
90 been recognized as a significant source of variation underlying complex diseases.¹⁸⁻²⁰ The widely
91 employed regression-based models characteristic of large-scale genetic/epidemiological studies of
92 complex disease, while adept at detecting linear, or additive, interaction effects, are not well
93 powered to detect non-linear interactions. In addition, the majority of studies investigating
94 interaction effects in complex diseases have utilized linear models in largely European populations.²¹⁻
95 ²³ Consequently, there is a significant lack of research investigating epistatic interaction effects
96 between environmental, psychosocial, demographic, and clinical factors in asthma research.
97 Furthermore, the lack of genetic research in non-European populations perpetuates asthma health
98 disparities, especially for those populations that carry a high disease burden, such as African
99 Americans.

100 Visualization of Statistical Epistasis Networks (ViSEN) is a statistical program that optimizes detection
101 of epistatic interactions through information-theoretic quantities, and is able to include multiple
102 types of data as discrete random variables.^{20,24} ViSEN is also able to identify and quantify both linear

103 and non-linear interactions and provide intuitive visualization of the potentially complex relationships
104 between large numbers of variables using a network-based approach. Additionally, ViSEN has been
105 shown to be more powerful than standard regression-based methods in detecting interaction effects,
106 suggesting that ViSEN is a promising investigative tool that can be applied to studies of complex
107 diseases such as BDR.^{20,24-28}

108 In this study, we conducted pairwise (two-variable) and higher order (three-variable) interaction
109 analyses using ViSEN to study the impact of both linear and epistatic interactions between social,
110 psychological, and biological variables on BDR in 617 African American youth with asthma. We then
111 performed these analyses in sex-stratified subsets to identify sex-specific effects in our study
112 population. Our study is the first to rigorously interrogate clinical, environmental, and demographic
113 information to identify hidden non-linear interactions affecting BDR in African American children with
114 asthma. By identifying previously overlooked epistatic interactions that significantly influence BDR in
115 African American youth with asthma; our study aims to provide novel information that can aid in
116 characterizing targets for future health intervention strategies and improving the design of future
117 studies of BDR.

118 **Results**

119 *Study Participants*

120 The SAGE study included African American participants aged 8 to 21 years with and without asthma.
121 Individuals without asthma and individuals missing any phenotype data were excluded from our analysis
122 (Table 1), yielding a total of 617 individuals with asthma (Males = 335, Females = 282). In the full
123 dataset, ViSEN analysis identified two variants independently associated with BDR status: sex ($p = 0.01$)
124 and perceived experience of discrimination ($p = 0.03$) (Table 1). All marginal effects of single variables,
125 defined by ViSEN as main effects, identified by ViSEN were also detected using standard descriptive

126 statistics (Table 1). Similarly, we explored the possibility of main effects in sex-stratified subsets of our
 127 population. For males, no independent effects were identified, while in females, global African ancestry
 128 was significantly associated with BDR responder
 129 status ($p = 0.02$, Additional File 1, Additional File 2).

130 **Table 1. Study Demographics**

			ViSEN	Descriptive Statistics	
Categorical Variable		BDR Responders	BDR Non-Responders	p-value [#]	p-value
Sample Size, N		171	446	---	---
Sex (% Female)		37%	49%	0.01	0.01 *
Age, yrs. (Mean, [SE])		(14, [0.275])	(14, [0.169])	0.93	0.77 ⁺
Body Mass Index	Obese	63	142	0.26	0.28*
	Non-Obese	108	304		
Experience of Discrimination	Yes	97	208	0.04	0.03 *
	No	74	238		
Prenatal Smoke Exposure	Yes	33	86	1.00	1.00*
	No	138	360		
Socioeconomic Status	> Low	116	290	0.57	0.57*
	Low	55	156		
Air Pollution (NO ₂)	≥ Median	91	217	0.35	0.36*
	< Median	80	229		
Global African Ancestry	≥ 80%	116	269	0.11	0.10*
	< 80%	55	177		

131 Summary statistics for all phenotypic data included for analysis in this study are presented above.
 132 Significant p-values are highlighted in **bold**. *p-values* represent the significance of the independent
 133 effects, or main effects, of specified variables on BDR responder status. [#]p-value calculated from ViSEN's
 134 Mutual Information (MI) Test. MI is a metric that quantifies the reduction in uncertainty about the
 135 distribution of one variable given an understanding of the other; * p-value calculated from Chi-squared
 136 Test of Independence; ⁺ p-value calculated from linear regression

137 *ViSEN Pairwise Interaction Effects*

138 We identified five significant pairwise (two-variable) interactions associated with BDR in the full dataset
 139 using ViSEN. ViSEN calculates the strength of an interaction's impact on BDR using an information-
 140 theory metric known as Information Gain (IG) (see Methods Section). Pairwise interaction models

141 significantly associated with BDR, in order of strength defined by Information Gain (IG) were: [1]
 142 prenatal smoke exposure and socioeconomic status (SES) (IG = 0.91%, p = 0.007), [2] experience of
 143 discrimination and SES (IG = 0.54%, p = 0.025), [3] age and body mass index (IG = 0.54%, p = 0.028), [4]
 144 sex and global African ancestry (IG = 0.49%, p = 0.036), and [5] experience of discrimination and prenatal
 145 smoke exposure (IG = 0.46%, p = 0.045) (Table 1A and Figure 1). Of these five significant pairwise
 146 interaction models, two models ([1] prenatal smoke exposure and SES ($\beta = -3.484$, p = 0.007) and [2] age
 147 and body mass index ($\beta = 2.577$, p = 0.014)) were also identified using linear regression analysis (Table
 148 1A).

149 **Table 2. ViSEN Interaction Models Significantly Associated with BDR in the Full Dataset.**

150 **A. Full Dataset**

Variable 1	Variable 2	ViSEN		Linear Regression	
		IG	p-value	β	p-value
Prenatal Smoke Exposure	SES ⁺	0.91%	0.007	-3.484	0.007
Experience of Discrimination	SES ⁺	0.54%	0.025	-0.656	0.532
Age	BMI [*]	0.54%	0.028	2.577	0.014
Sex	African Ancestry	0.49%	0.036	-0.148	0.886
Experience of Discrimination	Prenatal Smoke Exposure	0.46%	0.045	1.012	0.423

151 **B. Sex-Stratified Subsets**

Subset	Variable 1	Variable 2	ViSEN		Linear Regression	
			IG	p-value	β	p-value
FEMALE	Prenatal Smoke Exposure	SES ⁺	3.62%	< 0.001	-3.118	0.110
	Experience of Discrimination	SES ⁺	2.19%	0.008	-1.469	0.327
	Experience of Discrimination	African Ancestry	2.05%	0.008	0.628	0.680
MALE	---	---	---	---	---	---

152 Information Gain (IG) and *p-value* results for significant interaction models identified by ViSEN with corresponding
 153 liner regression results. Significant linear regression p-values are highlighted in **bold**. (A) ViSEN results for
 154 significant pairwise interactions in the full dataset. (B) ViSEN results for significant pairwise interaction in sex-
 155 stratified subsets of the full dataset. All ViSEN and linear regression models were adjusted for age, baseline lung
 156 function (Pre-FEV₁), and marginal effects of each independent variable included in the specified interaction model;
 157 analyses performed in the full dataset were also adjusted for sex. BMI^{*}: Body Mass Index; SES⁺: Socioeconomic
 158 Status; β : Beta value from linear regression model

159 ViSEN analysis of pairwise interactions performed in sex-stratified subsets of our study population
160 revealed disparate significant pairwise interaction effects among females and males. In females, the
161 three strongest pairwise interaction effects included: [1] prenatal smoke exposure and SES (IG = 3.62%,
162 $p < 0.001$), [2] experience of discrimination and SES (IG = 2.19%, $p = 0.008$), and [3] experience of
163 discrimination and global African ancestry (IG = 2.05%, $p = 0.008$) (Table 2B, Figure 2). Of the three
164 significant pairwise interaction effects uncovered by ViSEN, none were detectable using linear
165 regression analysis (Table 2B). There were no significant pairwise interaction models identified by either
166 ViSEN or linear regression in the male-only subset analysis.

167 *ViSEN Higher-Order (Three-Variable) Interaction Effects*

168 We identified four significant higher-order (three-variable) interactions associated with BDR in the full
169 dataset using ViSEN. Higher-order interaction models significantly associated with BDR, in order of
170 strength defined by IG, were: [1] prenatal smoke exposure, age, and African ancestry (IG = 1.09%, $p =$
171 0.005), [2] experience of discrimination, sex, and African ancestry (IG = 0.85%, $p = 0.011$), [3] prenatal
172 smoke exposure, sex, and SES (IG = 0.74%, $p = 0.023$), and [4] prenatal smoke exposure, age, and NO₂ air
173 pollution (IG = 0.65%, $p = 0.047$) (Table 3A and Figure 1). Of these four significantly associated
174 interaction models, only one model (prenatal smoke exposure, age, and African ancestry) was also
175 identified using linear regression analysis ($\beta = 6.268$, $p = 0.021$) (Table 3A).

176 ViSEN analysis of three-variable interactions performed in sex-stratified subsets of our study population
177 generated discordant results. In females, a single significant three-variable interaction model containing
178 NO₂ air pollution, body mass index, and SES (IG = 1.69%, $p = 0.026$; $\beta = -6.791$, $p = 0.032$) was detected by
179 both ViSEN and linear regression analysis (Table 3B, Figure 2). Conversely, there were two significant
180 three-variable interaction models identified by ViSEN in the male-only subset analysis: [1] prenatal
181 smoke exposure, experience of discrimination, and SES (IG = 1.53%, $p = 0.018$) and [2] prenatal smoke

182 exposure, age, and African ancestry (IG = 1.46%, p=0.024) (Table 3B, Figure 3). The interaction model in
 183 males containing prenatal smoke exposure, age, and African ancestry was also found to be significantly
 184 associated with BDR using linear regression analysis (β = 7.756, p= 0.035) (Table 3B).

185 **Table 3. Higher-Order Interaction Models Significantly Associated with BDR identified by ViSEN**

186 **A. Full Dataset**

Variable 1	Variable 2	Variable 3	ViSEN		Linear Regression	
			IG	p-value	β	p-value
Prenatal Smoke Exposure	Age	African Ancestry	1.09%	0.005	6.268	0.021
Experience of Discrimination	Sex	African Ancestry	0.85%	0.011	-1.386	0.501
Prenatal Smoke Exposure	Sex	SES ⁺	0.74%	0.023	-0.442	0.867
Prenatal Smoke Exposure	Age	Air Pollution (NO ₂)	0.65%	0.047	5.487	0.089

187 **B. Sex-Stratified Subsets**

Dataset	Variable 1	Variable 2	Variable 3	ViSEN		Linear Regression	
				IG	p-value	β	p-value
FEMALE	Air Pollution (NO ₂)	BMI*	SES ⁺	1.69%	0.026	-6.791	0.032
MALE	Prenatal Smoke Exposure	Experience of Discrimination	SES ⁺	1.53%	0.018	2.818	0.436
	Prenatal Smoke Exposure	Age	African Ancestry	1.46%	0.024	7.756	0.035

188 Information Gain (IG) and *p-value* results for significant interaction models associated with BDR
 189 identified by ViSEN with corresponding linear regression results. Significant linear regression p-values are
 190 highlighted in **bold**. All ViSEN and linear regression models were both adjusted for age, sex, baseline
 191 lung function (Pre-FEV₁), and marginal effects (what ViSEN calls “main effects”) of each variable included
 192 in the specified interaction model. (A) ViSEN results for three-way interaction in the full dataset. (B)
 193 ViSEN results for significant three-way interactions in sex-stratified subsets of the full dataset. BMI* :
 194 Body Mass Index; SES⁺: Socioeconomic Status; β : Beta value from linear regression model

195 **Discussion**

196 The high inter-individual variability of BDR between racial/ethnic populations may contribute to
 197 disparities in asthma morbidity and mortality observed in African American children with asthma. An
 198 existing pharmacogenomic study has characterized genetic components which may explain response to
 199 albuterol in this population.²⁹ Related studies have also noted ethnic-specific and other phenotypic
 200 differences in bronchodilator drug responsiveness.^{9,11,30} However, few have observed the joint effect of

201 variables influencing BDR. To the best of our knowledge, our study is the first to analyze the interaction
202 between clinical, genetic, environmental, and psychosocial factors affecting drug response in African
203 American children and adolescents using a non-parametric method optimized to detect epistatic
204 interactions. Here we demonstrate an integrative, investigative approach, which identifies novel gene-
205 environment epistatic interactions that may influence variability of BDR.

206 ViSEN consistently identified novel pairwise and higher-order interactions occurring within our study
207 population that, to our knowledge, have not been discussed elsewhere. Notably, the most informative
208 interaction occurring in females between prenatal smoke exposure and socioeconomic status (IG =
209 3.62%) was discovered completely independent of main effects for either variable. This was also true in
210 our full dataset where the interaction between prenatal smoke exposure and socioeconomic status (IG =
211 0.91%) was also identified in the absence of main effects for either variable. Importantly, of the nine
212 significant interaction effects identified by ViSEN in the full dataset, only three effects of these effects
213 were detected using linear regression. This trend was also seen in our sex stratified subset analyses;
214 linear regression detected only one of the four significantly associated interactions identified in females,
215 and only one of the two significantly associated interactions models uncovered by ViSEN in males. This
216 suggests that the majority of the interaction effects revealed by ViSEN are synergistic (non-linear) in
217 nature and therefore hidden when assessed using standard regression-based methods. It is also worth
218 noting that the interactions not detected by linear regression typically displayed greater Information
219 Gain (IG) metrics compared with those that were found by linear regression, further implying that non-
220 linear interactions may have a stronger impact on BDR than linear models.

221 Another interesting result of our study was the discordance of results between male and female only
222 subsets. Our results suggest the presence of significant sex-specific differences in the interactions
223 affecting BDR status. Another important revelation of our study was the strong effect of higher-order

224 interactions on BDR. In the full dataset, a three-variable interaction model had the strongest and most
225 significant association with BDR (Table 3A). This suggests that incorporating the study of more complex
226 models may lead to novel discoveries in this complex phenotype.

227 Interpreting results from ViSEN entails several considerations. The first consideration involves the nature
228 of the variables and their method of collection. BDR represents a clinical continuous measurement
229 obtained via spirometry, but other variables such as an experience of discrimination were collected via a
230 self-reported questionnaire. Therefore, there is a possibility that measurement error contributed to the
231 detection of interactions within this study, especially in variables that are not easily validated by
232 repeated measurements. However, in our study we have rigorously identified classifications for each
233 variable and validated our measurements by either consulting clinical guidelines or referencing previous
234 literature.^{13,14,31-34} All phenotype data included in this study has also been successfully used in other
235 studies relating to asthma phenotypes.^{13,14,31-34} Again, it is paramount to consider that regardless of the
236 rigor of data collection, ViSEN must collapse continuous variables into a ranked form and therefore
237 some information will be lost as result.

238 It should also be noted that while ViSEN can identify linear and non-linear interactions and quantify the
239 amount of information provided by these models, it does not provide the directionality of these effects
240 (i.e. whether interactions contribute positively/negatively to BDR responsiveness). To mitigate this
241 limitation for studies in which information on directionality of identified interaction effects would be
242 useful, it may be possible to supplement ViSEN analyses with additional post-hoc analyses such as
243 quantitative multifactor dimensionality reduction (qMDR) or the more familiar Dunn test, to aid in
244 further characterization of identified interaction effects.^{35,36} However, it should be noted that while
245 supplementation of ViSEN analysis in this way is possible, results from these post-hoc tests may not be

246 easily interpretable for every phenotype or interaction model. It will be the responsibility of individual
247 researchers to determine if their specific study lends itself to this type of further analyses.

248 **Conclusion**

249 Investigating epistatic gene-environment interactions is important to understanding variation in BDR in
250 the context of asthma outcomes, such as morbidity and mortality, and improving health equity across
251 the U.S. Social determinants of health are recognized as some the most predictive factors contributing
252 to individual health outcomes. Therefore, the inclusion of variables describing our “built environment”
253 (i.e. psychosocial factors such as socioeconomic status, experiences of discrimination, etc.) in gene-
254 environment interaction studies of BDR is crucial. Our study incorporated biological, environmental, and
255 psychosocial factors into a single comprehensive analysis of pairwise and higher-order interaction
256 models impacting BDR in African American youth with asthma. We identified novel interaction models
257 significantly impacting BDR in a population that carries a high disease burden (increased asthma
258 morbidity and mortality compared to European American children with asthma) and has been
259 historically understudied and underserved.

260 Parametric methods, such as generalized linear modeling, are the statistical tool of choice in most
261 scientific efforts to characterize interactions associated with BDR and other complex biological
262 phenotypes. The strength of using parametric methods is that they are well-understood and therefore
263 generally interpretable. However, methodology that is powered to detect only additive linear
264 relationships makes assumptions about the normality of variable sample distributions and the
265 distributional relationship of any identified interactions that may not hold true for many complex traits.
266 We contend that a significant portion of gene-environment interactions effecting complex phenotypes
267 like BDR are non-additive in nature, and the results of this study support this theory. The diversity and
268 complexity of the interactions impacting BDR should be embraced by employing non-parametric

269 methods such as ViSEN that are optimized to identify multiple types (linear/non-linear) gene-
270 environment interactions that might go undetected by less inclusive methods.

271 The nonparametric nature of ViSEN facilitates analyses that are more inclusive of the varying
272 relationships and interactions between health factors likely impacting complex clinical phenotypes
273 versus traditional linear modeling as we highlight in this study of BDR. Our study represents a
274 collaboration of computer science, biology, environmental epidemiology, and social epidemiology that
275 may lead to increased knowledge of asthma drug response and asthma morbidity in an “at-risk”
276 population. We believe that further collaboration between these fields is necessary to fully understand
277 the mechanism of action and impact of each interaction so that we incorporate novel findings into
278 actionable medical intervention that benefits all patients.

279 **Methods**

280 *Study Population*

281 The Study of African Americans, Asthma, Genes, & Environments (SAGE) is a case-control study
282 consisting of 1,710 participants ranging from ages 8 to 21 years old recruited from the San Francisco Bay
283 Area between 2008 and 2014. The SAGE study protocol and patient population have been previously
284 described in further detail, elsewhere.^{14,29,31} Briefly, all SAGE participants included in this study self-
285 identified as African American, as did their parents and all four grandparents. All participants presented
286 no history of other lung or chronic non-allergic illnesses upon study enrollment. Trained interviewers
287 administered questionnaires to the participants and/or the parents/caretakers of the participants to
288 collect basic demographic information, medical histories, and environmental exposure-related
289 information.¹⁴

290 Our study consisted of 617 participants with physician-diagnosed asthma from SAGE, with complete
291 data on sex, age, global African genetic ancestry, body mass index (BMI), any experience of

292 discrimination, socioeconomic status, prenatal smoke exposure, ambient NO₂ exposure over the first
293 year of life, and BDR (Additional File 3). Our sex-stratified subsets consisted of 335 and 282 male and
294 female individuals, respectively (Additional File 1 and Additional File 2). Appropriate descriptive statistics
295 for participants in the full dataset, as well as sex-stratified subsets, were generated using the R statistical
296 computing environment (Table 1, Additional File 1, and Additional File 2). ViSEN does not accommodate
297 continuous variables. Consequently, the outcome variable and all explanatory variables included in
298 interaction analyses were dichotomized prior to analysis as described below and in Additional File 3.

299 *Bronchodilator Drug Response (BDR)*

300 The primary outcome of this study is bronchodilator responder status. Responder status was
301 determined from individual spirometry measurements taken before and after administration of
302 albuterol. Following American Thoracic Society recommendations, pulmonary function was measured
303 prior to albuterol administration and then repeated 15 minutes after administration of four puffs (90
304 µg/puff) of albuterol.³⁷ This process was repeated a third time after a second dosage of albuterol: two
305 puffs for participants under the age of 16 and four puffs for older participants.²⁹ Asthma medications
306 were withheld from participants 12 hours before spirometry.³⁸ BDR (ΔFEV_1) was calculated as the mean
307 percentage change in measured Forced Expiratory Volume (FEV_1) before and after albuterol
308 administration, using the post-albuterol spirometry with the maximal change ($(\text{post-}FEV_1 - \text{pre-}FEV_1) /$
309 $\text{pre-}FEV_1) \times 100\%$. For each participant in this study, BDR (ΔFEV_1) was used to classify bronchodilator
310 responder status as either a responder, $\geq 12\%$, or a non-responder, $< 12\%$.³⁴ We excluded two
311 participants who were statistical outliers for BDR (raw values) as previously described.³⁹

312 Using a previously published protocol, deviance residual values generated from a generalized logistic
313 model ($BDR \sim \text{age} + \text{sex} + \text{pre-}FEV_1$) were employed to adjust dichotomized BDR values by age, sex, and
314 lung function.²⁸ Deviance residual values for BDR resulting from the GLM were then used to reclassify
315 individual responder status in the following manner: residual values $\geq 0\%$ were reclassified as

316 responders; residual values < 0% were reclassified as non-responders. Ultimately, reclassified responder
317 status was utilized as the outcome of interest for VISEN analysis. Individual BDR status was fully
318 concordant before and after covariate adjustment

319 *Age*

320 The participant's age was calculated as the difference between the age of enrollment (the date on the
321 eligibility form) and the date of birth. Discrete variables ranked from 0-1 were generated depending on
322 whether an individual was aged below (ranked 0), or at and above the median for the population
323 (ranked 1).

324 *Global African Ancestry*

325 Participants included in this study were previously genotyped using the Axiom® LAT1 array (World Array
326 4, Affymetrix, Santa Clara, CA).^{40,41} For every individual, we estimated the genetic proportion
327 contributed by an African ancestral population. These estimates, obtained using an unsupervised run of
328 ADMIXTURE, were considered as an average over each individual's entire genome to comprise a global
329 ancestry variable.⁴² Reference haplotypes of African and European individuals used in ADMIXTURE were
330 gathered from the HapMap phase III YRI and CEU populations.¹⁵ In this study, values for global African
331 ancestry were dichotomized according to their distribution above or equal to (1) or below (0) the U.S.
332 national average of 80% global African ancestry.⁴³

333 *Body Mass Index*

334 At the time of enrollment, each study participant was measured via a calibrated scale and stadiometer
335 for weight (kg) and height (m), respectively. Body mass index percentile values were subsequently
336 calculated through the following formula: $BMI = (kg) / (m^2)$. BMI percentile values were generated using
337 guidelines for BMI categories from the U.S. Centers for Disease and Control and Prevention Growth

338 Charts. BMI percentile values were dichotomized as either 0 or 1 depending on whether they fell below
339 (< 95%) or above/equal to (\geq 95%) the Obese BMI classification.¹⁶

340 *Perceived Experience of Discrimination*

341 Self-reported racial/ethnic discrimination was ascertained using the Experiences of Discrimination
342 Questionnaire.⁴⁴ Consistent with previous studies, we included questions pertaining to our population:
343 “Have you ever experienced discrimination, been prevented from doing something, or been hassled or
344 made to feel inferior, in any of the following situations because of your race, ethnicity, color, or
345 language? (1) At School; (2) Getting medical care; (3) Getting services in a store or restaurant; and (4) On
346 the street or in a public setting”; with choice for each question of *Yes* or *No*.^{45,46} Experiences of
347 discrimination were dichotomized as none or any (affirmative answer to at least one situation).
348 Interviewers required permission of caretakers to administer questions to participants equal to or less
349 than 16 years of age. Perceived experiences of discrimination were reported at time of recruitment.⁴⁶

350 *Prenatal Smoking*

351 Prenatal exposure to smoke was determined from questionnaire information regarding the self-
352 reported smoking status of participant’s mother during pregnancy. Binary values were assigned for
353 smoking status based on whether the mother was a non-smoker (0) or active smoker (1) during the
354 pregnancy of the participant.

355 *Socioeconomic Status*

356 We created a composite index for socioeconomic status (SES) derived from three socioeconomic
357 indicators: mother’s educational attainment, insurance status, and household income as previously
358 described.³² Each component variable was independently assigned a value scored on a three-point scale
359 ranging from low income (0), to medium income (1), to high income (2). Finally, for the purpose of our

360 study, individuals were classified as either having a low (0) or medium/high (1) composite
361 socioeconomic scores.

362 *Nitrogen Dioxide Exposure*

363 TomTom/Tele Atlas EZ-Locate software (TomTom, Amsterdam, The Netherlands) was utilized to assign
364 geographic coordinates for each participant's residential history. We collected regional ambient air
365 pollution data from the US Environmental Protection Agency Air Quality System based on these
366 geographic coordinates.¹³ Measures of average ambient NO₂ exposure (µg/ppb) were estimated over
367 the first year of each participant's life. If the participant moved during this period, NO₂ exposure was
368 weighted depending on the number of months spent at each residence. Discrete binary variables with
369 values 0 or 1 were generated depending on whether the individual was exposed to below (0) or greater
370 than/equal to the median NO₂ exposure (1) for the sample population within the first year of life.

371 *Visualization of Statistical Epistasis Networks (ViSEN)*

372 ViSEN is a statistical program used to perform network-based analyses that quantify and visualize
373 pairwise and higher-order epistatic interactions. Research suggests that ViSEN is more powerful than
374 standard regression-based methods for detecting nonlinear, non-additive interaction effects.^{19,26,33}
375 Effects of single explanatory variables, which ViSEN defines as main effects, on phenotype status is
376 calculated using Mutual Information (MI). MI, derived from information theory, quantifies the reduction
377 in uncertainty about the distribution of one variable given an understanding of the other. ViSEN
378 measures the strength of interaction effects on phenotype in terms of Information Gain (IG); IG is an
379 information-theoretical metric that quantifies how much additional phenotypic variance is explained by
380 jointly considering two or more variables versus an additive model of their individual effects. We
381 calculated pairwise (two-variable) and higher order (three-variable) interaction effects on BDR in the full
382 dataset and in gender-stratified subsets. To assess the significance of IG values computed from pairwise

383 and higher order interactions in our dataset, permutation (n=1000) was performed. Permutation
384 datasets were created by randomly shuffling BDR responder status. For each permuted dataset, the IG
385 was recomputed for every pairwise and higher order interaction model to form a null distribution of IG
386 values. *p-values* for IG calculations were generated by comparing the number of permutation-based IG
387 values equal to or larger than the IG value observed in our real dataset. In our study, we considered
388 interaction models with permutation *p-values* < 0.05 as statistically significant.

389 *Assessment of ViSEN identified Interactions using Linear Regression*

390 ViSEN has been shown to be more powerful than standard methods in identifying epistatic interactions.
391 However, since most previous interaction studies employed common statistical methods to identify
392 associations, it is possible that non-linear interactions that significantly impact phenotype were
393 overlooked.²⁰ Following the standard assumption in biomedical studies of additive main effects and
394 multiplicative interaction effects, we created multiplicative interaction terms to reflect each significant
395 interaction model identified by ViSEN. We then investigated whether any of the newly created
396 interaction terms was significantly associated with BDR using linear regression. For linear regression
397 analysis BDR was left as a continuous variable, and regression models were adjusted for age, sex, and
398 baseline lung function (pre-FEV₁), consistent with ViSEN models. Also consistent with ViSEN models,
399 regression models were additionally adjusted for the independent effects of all variants included in the
400 interaction terms as well as lower order interaction models included in the interaction term if
401 applicable. Linear regression models assessing pairwise interactions were coded as follows: BDR ~ age +
402 sex + FEV1 + variable1 + variable2 + variable1*variable2 (pairwise interaction term). Linear regression
403 models assessing higher-order (three-variable) interaction terms were coded as follows: BDR ~ age + sex
404 + FEV1 + variable1 + variable2 + variable3 + variable1*variable2 + variable2*variable3 + variable
405 1*variable3 + variable1*variable2*variable3 (three-variable interaction term). All regression analyses
406 were performed in R.⁴⁷

407 **Declarations**

408 *Ethics approval and Consent to Participate*

409 A total of 617 participants from the SAGE study were used to generate the results described in this
410 manuscript. The SAGE study was approved by the Institutional Review Board of the University of
411 California San Francisco (Laurel Heights Panel) (IRB# 10-02877; Reference # 271317). All participants 18
412 years of age at the time of study enrollment provided their written consent to participate in this study.
413 Parents of participants under 18 years of age provided their written assent for the participation of their
414 children in this study.

415 *Consent for publication*

416 Not Applicable

417 *Availability of data and materials*

418 Biological, environmental and phenotypic data analyzed in the current study are available in the dbGAP
419 repository (study accession number phs00921.v1.p1). Psychosocial data analyzed in the current study
420 (experience of discrimination and socioeconomic status) are not publicly available due to the sensitive
421 nature of the data and privacy concerns for study participants. Psychosocial data is currently stored in
422 the UCSF Box repository and is available from the corresponding author upon reasonable request
423 (<https://ucsf.box.com/s/2cx8v52u1ouql02w8io3mhwe2tzell5m>).

424 *Competing Interests*

425 The authors declare that they have no competing interests.

426 *Funding*

427 The acquisition and analysis of data in this work was supported in part by the Sandler Family
428 Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program,
429 the National Heart, Lung, and Blood Institute (NHLBI) R01HL117004, R01HL128439, R01HL135156,
430 X01HL134589, R01HL141992, and R01HL104608, the National Institute of Environmental Health
431 Sciences R01ES015794, R21ES24844, the National Institute on Minority Health and Health Disparities
432 P60MD006902, R01MD010443, and RL5GM118984, and the Tobacco-Related Disease Research Program
433 24RT-0025. The research effort of J.M. was additionally supported by a diversity supplement of NIMHD
434 R01MD010443. The research effort of K.L.K was additionally supported by a diversity supplement of
435 NHLBI R01HL135156, the UCSF Bakar Computational Health Sciences Institute, the Gordon and Betty
436 Moore Foundation grant GBMF3834, and the Alfred P. Sloan Foundation grant 2013-10-27 to UC
437 Berkeley through the Moore-Sloan Data Sciences Environment initiative at the Berkeley Institute for
438 Data Science (BIDS). The research effort of M.J.W. was additionally supported by an NHLBI Research
439 Career Development (K) Award K01HL140218. The research effort of M.G.C was additionally supported
440 by NIH MARC U-STAR grant T34GM008574 at San Francisco State University. SF BUILD, San Francisco
441 State University, San Francisco, CA, USA.

442 *Authors' Contributions*

443 J.M. and M.J.W. designed the current study, drafted the manuscript, and analyzed and interpreted the
444 data. K.L.K. and M.G.C. made substantial contributions to data interpretation and drafted the
445 manuscript. A.C.Y.M., D.H., N.T., C.E., S.H., J.R.E., and S.S. generated covariate data and substantively
446 revised the manuscript. O.R.A., P.G.C., A.Z., L.A.S.B., and E.L. made substantial contributions to
447 manuscript revisions. T.H. interpreted the data, computed ViSEN p-values, and made substantial
448 revisions to the manuscript draft. E.G.B. conceived and designed the SAGE study cohort, facilitated the

449 acquisition of clinical and environmental data analyzed in the manuscript, and made substantial
450 revisions to the manuscript draft.

451 *Acknowledgements*

452 The authors wish to acknowledge the following SAGE co-investigators for subject recruitment, sample
453 processing and quality control: Luisa N. Borrell, DDS, PhD, Emerita Brigino-Buenaventura, MD, Adam
454 Davis, MA, MPH, Michael A. LeNoir, MD, Kelley Meade, MD, Fred Lurmann, MS and Harold J. Farber,
455 MD, MSPH. The authors also wish to thank the staff and participants who contributed to the SAGE study.

456 **References**

- 457 **1.** Mims JW. Asthma: definitions and pathophysiology.
- 458 **2.** Adams PF, Hendershot GE, Marano MA, Centers for Disease Control and Prevention/National
459 Center for Health S. Current estimates from the National Health Interview Survey, 1996.
- 460 **3.** Akinbami LJ, Moorman JE, Simon AE, Schoendorf KC. Trends in racial disparities for asthma
461 outcomes among children 0 to 17 years, 2001-2010. *J Allergy Clin Immunol.* 2014;134(3):547-
462 553.e545.
- 463 **4.** Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United
464 States, 2005-2009. *Natl Health Stat Report.* 2011(32):1-14.
- 465 **5.** Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nature.* 2016;538(7624):161-164.
- 466 **6.** Oh SS, White MJ, Gignoux CR, Burchard EG. Making Precision Medicine Socially Precise. Take a
467 Deep Breath. *Am J Respir Crit Care Med.* 2016;193(4):348-350.
- 468 **7.** Forno E, Celedon JC. Asthma and ethnic minorities: socioeconomic status and beyond. *Curr Opin*
469 *Allergy Clin Immunol.* 2009;9(2):154-160.
- 470 **8.** Barnes PJ. Drugs for asthma. *Br J Pharmacol.* 2006;147 Suppl 1:S297-303.
- 471 **9.** Choudhry S, Ung N, Avila PC, et al. Pharmacogenetic differences in response to albuterol
472 between Puerto Ricans and Mexicans with asthma. *Am J Respir Crit Care Med.* 2005;171(6):563-
473 570.
- 474 **10.** Burchard EG, Avila PC, Nazario S, et al. Lower bronchodilator responsiveness in Puerto Rican
475 than in Mexican subjects with asthma. *Am J Respir Crit Care Med.* 2004;169(3):386-392.

- 476 **11.** Naqvi M, Thyne S, Choudhry S, et al. Ethnic-specific differences in bronchodilator responsiveness
477 among African Americans, Puerto Ricans, and Mexicans with asthma. *J Asthma*. 2007;44(8):639-
478 648.
- 479 **12.** McGeachie MJ, Stahl EA, Himes BE, et al. Polygenic Heritability Estimates in Pharmacogenetics:
480 Focus on Asthma and Related Phenotypes. *Pharmacogenet Genomics*. 2013;23(6):324-328.
- 481 **13.** Neophytou AM, White MJ, Oh SS, et al. Air Pollution and Lung Function in Minority Youth with
482 Asthma in the GALA II (Genes-Environments and Admixture in Latino Americans) and SAGE II
483 (Study of African Americans, Asthma, Genes, and Environments) Studies. *Am J Respir Crit Care*
484 *Med*. 2016;193(11):1271-1280.
- 485 **14.** Nishimura KK, Galanter JM, Roth LA, et al. Early-life air pollution and asthma risk in minority
486 children. The GALA II and SAGE II studies. *Am J Respir Crit Care Med*. 2013;188(3):309-318.
- 487 **15.** Pino-Yanes M, Thakur N, Gignoux CR, et al. Genetic ancestry influences asthma susceptibility
488 and lung function among Latinos. *J Allergy Clin Immunol*. 2015;135(1):228-235.
- 489 **16.** McGarry ME, Castellanos E, Thakur N, et al. Obesity and bronchodilator response in black and
490 Hispanic children and adolescents with asthma. *Chest*. 2015;147(6):1591-1598.
- 491 **17.** Moore JH, Williams SM. Epistasis and its implications for personal genetics. *Am J Hum Genet*.
492 2009;85(3):309-320.
- 493 **18.** Cordell HJ. Detecting gene-gene interactions that underlie human diseases. *Nat Rev Genet*.
494 2009;10(6):392-404.
- 495 **19.** Moore JH. A global view of epistasis. *Nat Genet*. 2005;37(1):13-14.

- 496 **20.** Hu T, Chen Y, Kiralis JW, Moore JH. ViSEN: methodology and software for visualization of
497 statistical epistasis networks. *Genet Epidemiol.* 2013;37(3):283-285.
- 498 **21.** Oh SS, Galanter J, Thakur N, et al. Diversity in Clinical and Biomedical Research: A Promise Yet to
499 Be Fulfilled. *PLoS Med.* 2015;12(12):e1001918.
- 500 **22.** Thomson GE, Mitchell F, Williams MB. Examining the Health Disparities Research Plan of the
501 National Institutes of Health: Unfinished Business. *Institute of Medicine.* 2006. Washington, DC:
502 The National Academies Press. <https://doi.org/10.17226/11602>.
- 503 **23.** Burchard EG, Oh SS, Foreman MG, Celedón JC. Moving toward true inclusion of racial/ethnic
504 minorities in federally funded studies. A key step for achieving respiratory health equality in the
505 United States. *Am J Respir Crit Care Med.* 2015;191(5):514-521.
- 506 **24.** Hu T, Sinnott-Armstrong NA, Kiralis JW, Andrew AS, Karagas MR, Moore JH. Characterizing
507 genetic interactions in human disease association studies using statistical epistasis networks.
508 *BMC Bioinformatics.* 2011;12:364.
- 509 **25.** Chanda P, Sucheston L, Zhang A, Ramanathan M. The interaction index, a novel information-
510 theoretic metric for prioritizing interacting genetic variations and environmental factors. *Eur J*
511 *Hum Genet.* 2009;17(10):1274-1286.
- 512 **26.** White MJ, Eren F, Ağırbaşı D, et al. A systems genetics approach to dyslipidemia in children and
513 adolescents. *OMICS.* 2015;19(4):248-259.
- 514 **27.** White MJ, Tacconelli A, Chen JS, et al. Epiregulin (EREG) and human V-ATPase (TCIRG1): genetic
515 variation, ethnicity and pulmonary tuberculosis susceptibility in Guinea-Bissau and The Gambia.
516 *Genes Immun.* 2014;15(6):370-377.

- 517 **28.** De R, Hu T, Moore JH, Gilbert-Diamond D. Characterizing gene-gene interactions in a statistical
518 epistasis network of twelve candidate genes for obesity. *BioData Min.* 2015;8:45.
- 519 **29.** Mak ACY, White MJ, Eckalbar WL, et al. Whole-Genome Sequencing of Pharmacogenetic Drug
520 Response in Racially Diverse Children with Asthma. *Am J Respir Crit Care Med.*
521 2018;197(12):1552-1564.
- 522 **30.** Burchard EG, Avila PC, Nazario S, et al. Lower bronchodilator responsiveness in Puerto Rican
523 than in Mexican subjects with asthma. *Am J Respir Crit Care Med.* 2004;169(3):386-392.
- 524 **31.** Borrell LN, Nguyen EA, Roth LA, et al. Childhood obesity and asthma control in the GALA II and
525 SAGE II studies. *Am J Respir Crit Care Med.* 2013;187(7):697-702.
- 526 **32.** Thakur N, Oh SS, Nguyen EA, et al. Socioeconomic status and childhood asthma in urban
527 minority youths. The GALA II and SAGE II studies. *Am J Respir Crit Care Med.* 2013;188(10):1202-
528 1209.
- 529 **33.** White MJ, Risse-Adams O, Goddard P, et al. Novel genetic risk factors for asthma in African
530 American children: Precision Medicine and the SAGE II Study. *Immunogenetics.* 2016;68(6-
531 7):391-400.
- 532 **34.** Guidelines for the Diagnosis and Management of Asthma (EPR-3) | National Heart, Lung, and
533 Blood Institute (NHLBI) Standardization of Spirometry, 1994 Update. American Thoracic Society.
- 534 **35.** Hadley Wickham, Romain François, Lionel Henry and Kirill Müller (2020). dplyr: A Grammar of
535 Data Manipulation. R package version 0.8.4. <https://CRAN.R-project.org/package=dplyr>

- 536 **36.** Gui J, Moore JH, Williams SM, et al. A Simple and Computationally Efficient Approach to
537 Multifactor Dimensionality Reduction Analysis of Gene-Gene Interactions for Quantitative Traits.
538 *PLoS One*. 2013;8(6):e66545.
- 539 **37.** Hallstrand TS, Fischer ME, Wurfel MM, Afari N, Buchwald D, Goldberg J. Genetic pleiotropy
540 between asthma and obesity in a community-based sample of twins. *The Journal of allergy and*
541 *clinical immunology*. 2005;116(6):1235-1241.
- 542 **38.** Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur*
543 *Respir J*. 2005;26(5):948-968.
- 544 **39.** Spear ML, Hu D, Pino-Yanes M, et al. A genome-wide association and admixture mapping study
545 of bronchodilator drug response in African Americans with asthma. *Pharmacogenomics J*.
546 2019;19(3):249-259.
- 547 **40.** Hoffmann TJ, Zhan Y, Kvale MN, et al. Design and coverage of high throughput genotyping arrays
548 optimized for individuals of East Asian, African American, and Latino race/ethnicity using
549 imputation and a novel hybrid SNP selection algorithm. *Genomics*. 2011;98(6):422-430.
- 550 **41.** Galanter JM, Gignoux CR, Torgerson DG, et al. Genome-wide association study and admixture
551 mapping identify different asthma-associated loci in Latinos: the Genes-environments &
552 Admixture in Latino Americans study. *J Allergy Clin Immunol*. 2014;134(2):295-305.
- 553 **42.** Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated
554 individuals. *Genome Res*. 2009;19(9):1655-1664.
- 555 **43.** Baharian S, Barakatt M, Gignoux CR, et al. The Great Migration and African-American Genomic
556 Diversity. *PLoS Genet*. 2016;12(5):e1006059.

- 557 **44.** Krieger N, Smith K, Naishadham D, Hartman C, Barbeau EM. Experiences of discrimination:
558 validity and reliability of a self-report measure for population health research on racism and
559 health. *Soc Sci Med.* 2005;61(7):1576-1596.
- 560 **45.** Thakur N, Barcelo NE, Borrell LN, et al. Perceived Discrimination Associated With Asthma and
561 Related Outcomes in Minority Youth: The GALA II and SAGE II Studies. *Chest.* 2017;151(4):804-
562 812.
- 563 **46.** Carlson S, Borrell LN, Eng C, et al. Self-reported racial/ethnic discrimination and bronchodilator
564 response in African American youth with asthma. *PLoS One.* 2017;12(6):e0179091.
- 565 **47.** R Core Team (2019). R: A language and environment for statistical computing. R Foundation for
566 Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.

567 **Figure Titles and Legends**

568 **Figure 1. Visualization of Interaction Network in the Full Dataset.** Visual representation of the
569 interaction network for all significant interaction effects identified by ViSEN for the full dataset. The size
570 of an individual node corresponds to the amount of Mutual Information (MI) resulting from the
571 independent main effects of each variable. The strength of significant pairwise interactions corresponds
572 to the thickness of the lines connecting independent nodes along the network. Triangles and dotted
573 lines represent a significant three-way interaction effect between variables.

574 **Figure 2. Visualization of Interaction Network in Females.** Visual representation of the interaction
575 network for all significant effects generated in ViSEN for female only subset. The size of an individual
576 node corresponds to the amount of Mutual Information (MI) resulting from the independent main
577 effects of each variable. The strength of significant pairwise interactions corresponds to the thickness of

578 the lines connecting independent nodes along the network. Triangles and dotted lines represent a
579 significant three-way interaction effect between variables.

580 **Figure 3. Visualization of Interaction Network in Males.** Visual representation of the interaction
581 network for all significant effects generated in ViSEN for the male-only subset. The size of an individual
582 node corresponds to the amount of Mutual Information (MI) resulting from the independent main
583 effects of each variable. Triangles and dotted lines represent a significant three-way interaction effect
584 between variables.

585 **Additional Files**

586 File name: Additional File 1

587 File format: .docx

588 Title of data: Supplemental Table 1. Female Subset Demographics

589 Description of data: Demographic information for female-only subset analyses

590 File name: Additional File 2

591 File format: .docx

592 Title of data: Supplemental Table 2. Male Subset Demographics

593 Description of data: Demographic information for male-only subset analyses

594 File name: Additional File 3

595 File format: .docx

596 Title of data: Supplemental Table 3. Phenotypic data included for analysis in this study

597 Description of data: Description and categorization of data included in ViSEN analyses





